Nordicus Partners Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Nordicus Partners Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Mar 31, 2019 | $3.3K | Aug 23, 2019 |
| FY2019 | Mar 31, 2018 | $2.9K | Aug 23, 2019 |
| FY2018 | Mar 31, 2017 | $2.28M | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | $3.18M | Jun 26, 2017 |
| FY2016 | Mar 31, 2015 | $3.18M | Jun 27, 2016 |
| FY2016 | Mar 31, 2014 | $2.57M | Jun 27, 2016 |
| FY2014 | Mar 31, 2013 | $2.20M | Jul 29, 2014 |
| FY2012 | Mar 31, 2012 | $1.87M | Jul 17, 2013 |
| FY2011 | Mar 31, 2011 | $1.67M | Nov 13, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $5.0K | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | $2.5K | Jul 29, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Mar 31, 2019 | $2.5K | Aug 23, 2019 |
| FY2019 | Mar 31, 2018 | $2.1K | Aug 23, 2019 |
| FY2018 | Mar 31, 2017 | $1.43M | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | $2.10M | Jun 26, 2017 |
| FY2016 | Mar 31, 2015 | $2.10M | Jun 27, 2016 |
| FY2016 | Mar 31, 2014 | $1.65M | Jun 27, 2016 |
| FY2014 | Mar 31, 2013 | $1.38M | Jul 29, 2014 |
| FY2012 | Mar 31, 2012 | $969.0K | Jul 17, 2013 |
| FY2011 | Mar 31, 2011 | $143.0K | Nov 13, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($2.90M) | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | ($298.2K) | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | ($8.47M) | Jul 3, 2024 |
| FY2023 | Mar 31, 2022 | ($287.2K) | Jul 20, 2023 |
| FY2022 | Mar 31, 2021 | ($326.0K) | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | $5.45M | Sep 22, 2021 |
| FY2020 | Mar 31, 2019 | $334.0K | Jul 16, 2021 |
| FY2018 | Mar 31, 2018 | ($202.0K) | Jul 16, 2018 |
| FY2018 | Mar 31, 2017 | ($509.0K) | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | $33.0K | Jun 26, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($2.92M) | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | ($307.6K) | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | ($8.48M) | Jul 3, 2024 |
| FY2023 | Mar 31, 2022 | ($309.2K) | Jul 20, 2023 |
| FY2022 | Mar 31, 2021 | ($326.0K) | Jun 28, 2022 |
| FY2019 | Mar 31, 2019 | $751 | Aug 23, 2019 |
| FY2019 | Mar 31, 2018 | $181 | Aug 23, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.33M | Jul 29, 2025 |
| FY2020 | Jan 31, 2020 | $314.0K | Jul 16, 2021 |
| FY2019 | Mar 31, 2019 | $345 | Aug 23, 2019 |
| FY2019 | Mar 31, 2018 | $375 | Aug 23, 2019 |
| FY2018 | Mar 31, 2017 | $329.0K | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | $310.0K | Jun 26, 2017 |
| FY2016 | Mar 31, 2015 | $310.0K | Jun 27, 2016 |
| FY2016 | Mar 31, 2014 | $356.0K | Jun 27, 2016 |
| FY2014 | Mar 31, 2013 | $444.0K | Jul 29, 2014 |
| FY2012 | Mar 31, 2012 | $605.0K | Jul 17, 2013 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Mar 31, 2019 | $1.4K | Aug 23, 2019 |
| FY2019 | Mar 31, 2018 | $1.6K | Aug 23, 2019 |
| FY2018 | Mar 31, 2017 | $1.24M | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | $1.39M | Jun 26, 2017 |
| FY2016 | Mar 31, 2015 | $1.39M | Jun 27, 2016 |
| FY2016 | Mar 31, 2014 | $1.22M | Jun 27, 2016 |
| FY2014 | Mar 31, 2013 | $1.61M | Jul 29, 2014 |
| FY2012 | Mar 31, 2012 | $1.84M | Jul 17, 2013 |
| FY2011 | Mar 31, 2011 | $2.49M | Nov 13, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($1.28M) | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | ($258.9K) | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | ($368.3K) | Jul 3, 2024 |
| FY2023 | Mar 31, 2022 | ($282.4K) | Jul 20, 2023 |
| FY2022 | Mar 31, 2021 | ($323.0K) | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | $5.33M | Sep 22, 2021 |
| FY2020 | Mar 31, 2019 | ($31.0K) | Jul 16, 2021 |
| FY2018 | Mar 31, 2018 | $108.0K | Jul 16, 2018 |
| FY2018 | Mar 31, 2017 | ($203.0K) | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | $62.0K | Jun 26, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $70.25M | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | $1.81M | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | $55.0K | Jul 3, 2024 |
| FY2023 | Mar 31, 2022 | $249.4K | Jul 20, 2023 |
| FY2022 | Mar 31, 2021 | $128.0K | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | $5.61M | Sep 22, 2021 |
| FY2020 | Mar 31, 2019 | $2.98M | Jul 16, 2021 |
| FY2019 | Mar 31, 2018 | $2.9K | Aug 23, 2019 |
| FY2018 | Mar 31, 2017 | $2.43M | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | $2.58M | Jun 26, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $10.38M | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | $26.4K | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | $27.4K | Jul 3, 2024 |
| FY2023 | Mar 31, 2022 | $54.9K | Jul 20, 2023 |
| FY2022 | Mar 31, 2021 | $46.0K | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | $114.0K | Sep 22, 2021 |
| FY2020 | Mar 31, 2019 | $3.13M | Jul 16, 2021 |
| FY2019 | Mar 31, 2018 | $3.4K | Aug 23, 2019 |
| FY2018 | Mar 31, 2017 | $3.03M | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | $2.67M | Jun 26, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $59.87M | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | $1.78M | Jul 29, 2025 |
| FY2025 | Mar 31, 2023 | $27.7K | Jul 29, 2025 |
| FY2024 | Mar 31, 2022 | $194.5K | Jul 3, 2024 |
| FY2023 | Mar 31, 2021 | $81.7K | Jul 20, 2023 |
| FY2022 | Mar 31, 2020 | $5.50M | Jun 28, 2022 |
| FY2021 | Mar 31, 2019 | ($146.0K) | Sep 22, 2021 |
| FY2020 | Mar 31, 2018 | ($503.0K) | Jul 16, 2021 |
| FY2018 | Mar 31, 2017 | ($601.0K) | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | ($96.0K) | Jun 26, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $25.49M | Jul 29, 2025 |
| FY2025 | May 13, 2024 | $7.09M | Jul 29, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($46.78M) | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | ($43.88M) | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | ($42.20M) | Jul 3, 2024 |
| FY2023 | Mar 31, 2022 | ($33.73M) | Jul 20, 2023 |
| FY2022 | Mar 31, 2021 | ($33.44M) | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | ($33.11M) | Sep 22, 2021 |
| FY2020 | Mar 31, 2019 | ($38.56M) | Jul 16, 2021 |
| FY2019 | Mar 31, 2018 | ($38.9K) | Aug 23, 2019 |
| FY2018 | Mar 31, 2017 | ($38.70M) | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | ($38.19M) | Jun 26, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | $7.1K | Jul 20, 2023 |
| FY2023 | Mar 31, 2022 | $245.9K | Jul 20, 2023 |
| FY2022 | Mar 31, 2021 | $128.0K | Jun 28, 2022 |
| FY2019 | Mar 31, 2019 | $172 | Aug 23, 2019 |
| FY2019 | Mar 31, 2018 | $120 | Aug 23, 2019 |
| FY2019 | Mar 31, 2017 | $27 | Aug 23, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | (1) | Jul 3, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Jul 20, 2023 |
| FY2022 | Mar 31, 2021 | 0 | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | 0 | Sep 22, 2021 |
| FY2020 | Mar 31, 2019 | 0 | Jul 16, 2021 |
| FY2019 | Mar 31, 2018 | 0 | Aug 23, 2019 |
| FY2018 | Mar 31, 2017 | 0 | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | 0 | Jun 26, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jul 29, 2025 |
| FY2024 | Mar 31, 2023 | (1) | Jul 3, 2024 |
| FY2021 | Mar 31, 2021 | 0 | Sep 22, 2021 |
| FY2021 | Mar 31, 2020 | 0 | Sep 22, 2021 |
| FY2020 | Mar 31, 2019 | 0 | Jul 16, 2021 |
| FY2019 | Mar 31, 2018 | 0 | Aug 23, 2019 |
| FY2018 | Mar 31, 2017 | 0 | Jul 16, 2018 |
| FY2017 | Mar 31, 2016 | 0 | Jun 26, 2017 |
| FY2016 | Mar 31, 2015 | 0 | Jun 27, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 17.25M | Jul 29, 2025 |
| FY2025 | Mar 31, 2024 | 1.11M | Jul 29, 2025 |
| FY2023 | Mar 31, 2023 | 5.68M | Jul 20, 2023 |
| FY2023 | Mar 31, 2022 | 5.68M | Jul 20, 2023 |
| FY2022 | Mar 31, 2021 | 566,773 | Jun 28, 2022 |
| FY2021 | Mar 31, 2020 | 28.26M | Sep 22, 2021 |
| FY2020 | Mar 31, 2019 | 21.49M | Jul 16, 2021 |
| FY2019 | Mar 31, 2018 | 21.49M | Aug 23, 2019 |